Suzhou Qianyuan Biotechnology

Suzhou Qianyuan Biotechnology is a Chinese biopharmaceutical company specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. The company leverages a proprietary differentiation and expansion platform to produce high-purity functional cells, such as hepatocytes and natural killer cells, for clinical applications. Qianyuan Bio's primary focus is on regenerative medicine for end-stage liver diseases and off-the-shelf immunotherapy for solid tumors. Based in the Suzhou Industrial Park (BioBAY), the firm aims to address the shortage of donor organs and the limitations of primary cell therapies. Their pipeline includes preclinical programs designed to provide standardized, scalable cell-based treatments.